CellCentric Presents Positive Phase 2 Dose Optimization Data for Inobrodib in Multiple Myeloma at ASH Annual Meeting @CellCentric #ASH #CellCentric #Inobrodib #MulitpleMyeloma #Oncology #Chemicals #Biotechnology #AGM #AnnualMeeting
- Inobrodib in combination with pomalidomide + dexamethasone (InoPd) demonstrates strong clinical efficacy and a tolerable safety profile in heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients -- Observed response rates of 60-75% with inobrodib 20 mg and 30 mg cohorts result in clinical efficacy at least two-fold higher than previously published real-world data for pom-refractory, bispecific or anti-BCMA exposed patients -Cambridge, United Kingdom and Boston,...
http://dlvr.it/TPh16n
http://dlvr.it/TPh16n
Comments
Post a Comment